[{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Garvan Institute of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Microba Life Sciences \/ Garvan Institute of Medical Research","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Garvan Institute of Medical Research"},{"orgOrder":0,"company":"BioCina","sponsor":"Australian Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"BioCina","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCina \/ Australian Government","highestDevelopmentStatusID":"2","companyTruncated":"BioCina \/ Australian Government"},{"orgOrder":0,"company":"oNKo-innate","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"oNKo-innate","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"oNKo-innate \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"oNKo-innate \/ Gilead Sciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The project, commencing in March will help BioCina address the post-pandemic mRNA demand for specific and essential attributes of new RNA products. It's anticipated the market will prioritize sophisticated LNP (lipid nanoparticle) formulations.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 04, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Australian Government

                          Deal Size : $8.3 million

                          Deal Type : Funding

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Microba’s Cancer Immuno-Oncology Neoadjuvant Therapy is targeting discovery and development of a microbiome therapy to improve response rates in cancer patients receiving immune checkpoint inhibitor (ICI) therapy, with a specific focus on Melanoma and ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Garvan Institute of Medical Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Collaboration will leverage Onko-Innate’s deep expertise in NK Cell Tumor Biology to discover novel therapies in immuno-oncology and cell therapy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 21, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank